Lista de obras -

"I Can Breathe Again!" Patients' Self-Management Strategies for Episodic Breathlessness in Advanced Disease, Derived From Qualitative Interviews.

artículo científico publicado en 2016

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma

artículo científico publicado en 2011

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.

artículo científico publicado en 2016

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

artículo científico publicado en 2017

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

artículo científico publicado en 2018

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

artículo científico publicado en 2019

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer

artículo científico publicado en 2014

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

artículo científico publicado en 2015

AllergoOncology - the impact of allergy in oncology: EAACI position paper.

artículo científico publicado en 2016

AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody

artículo científico publicado en 2019

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.

artículo científico publicado en 2017

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

artículo científico publicado en 2018

An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.

artículo científico publicado en 2018

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer

artículo científico publicado en 2018

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling

artículo científico publicado en 2017

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).

artículo científico publicado en 2017

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

artículo científico

BRAF inhibitors: resistance and the promise of combination treatments for melanoma

artículo científico publicado en 2017

Beta-glucan contamination of pharmaceutical products: How much should we accept?

artículo científico publicado en 2016

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

artículo científico publicado en 2017

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial

artículo científico publicado en 2017

Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring

artículo científico publicado en 2013

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

article

Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.

artículo científico publicado en 2014

Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer

artículo científico publicado en 2013

Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies.

artículo científico publicado en 2016

Differential Survival characteristics of sarcomatoid subtype biphasic pleural mesothelioma

artículo científico publicado en 2018

EGFR inhibition and more: a new generation growing up ⬇️

artículo científico publicado el 1 de diciembre de 2012

EGFR-mutated lung cancer in Li-Fraumeni syndrome.

artículo científico publicado en 2014

Embracing model-based designs for dose-finding trials. ⬇️

artículo científico publicado en 2017

Episodic and continuous breathlessness: a new categorization of breathlessness.

artículo científico publicado en 2012

Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells

artículo científico publicado en 2018

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer.

artículo científico publicado en 2018

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

artículo científico publicado en 2011

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

artículo científico publicado en 2015

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer

artículo científico publicado en 2014

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.

artículo científico publicado en 2017

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients.

artículo científico publicado en 2018

HOX transcription factors are potential targets and markers in malignant mesothelioma

artículo científico publicado en 2015

IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.

artículo científico publicado en 2016

IgE immunotherapy: a novel concept with promise for the treatment of cancer

artículo científico publicado en 2014

IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states

scientific article published on 05 April 2019

IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin

scientific article published on 14 July 2016

Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma

artículo científico publicado en 2019

Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma ⬇️

artículo científico publicado el 20 de diciembre de 2010

Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.

artículo científico publicado en 2017

LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1 ⬇️

artículo científico publicado el 1 de diciembre de 2001

MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial

artículo científico publicado en 2020

Microdroplet digital PCR: detection and quantitation of biomarkers in archived tissue and serial plasma samples in patients with lung cancer

artículo científico

Nedaplatin: a new platinum for squamous lung cancer?

artículo científico publicado en 2015

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with

artículo científico publicado en 2018

Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication

artículo científico publicado en 2013

Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations

artículo científico publicado en 2014

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers

artículo científico publicado en 2017

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

artículo científico publicado en 2013

Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience

artículo científico publicado en 2015

Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).

artículo científico publicado en 2016

Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer

artículo científico publicado en 2018

Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer ⬇️

artículo científico publicado el 1 de agosto de 2012

Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.

artículo científico publicado en 2011

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009.

artículo científico publicado en 2013

Targeting folate receptor alpha for cancer treatment

artículo científico publicado en 2016

The impact of socioeconomic status on access to cancer clinical trials

artículo científico publicado en 2014

The role of the HGF/Met axis in mesothelioma.

artículo científico publicado en 2016

Therapeutic targets and new directions for antibodies developed for ovarian cancer.

artículo científico publicado en 2016

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial

artículo científico publicado en 2019

Lista de obras de

"I Can Breathe Again!" Patients' Self-Management Strategies for Episodic Breathlessness in Advanced Disease, Derived From Qualitative Interviews.

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

AllergoOncology - the impact of allergy in oncology: EAACI position paper.

AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

BRAF inhibitors: resistance and the promise of combination treatments for melanoma

Beta-glucan contamination of pharmaceutical products: How much should we accept?

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial

Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.

Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer

Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies.

Differential Survival characteristics of sarcomatoid subtype biphasic pleural mesothelioma

EGFR inhibition and more: a new generation growing up ⬇️

EGFR-mutated lung cancer in Li-Fraumeni syndrome.

Embracing model-based designs for dose-finding trials. ⬇️

Episodic and continuous breathlessness: a new categorization of breathlessness.

Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer.

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients.

HOX transcription factors are potential targets and markers in malignant mesothelioma

IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.

IgE immunotherapy: a novel concept with promise for the treatment of cancer

IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states

IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin

Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma

Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma ⬇️

Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.

LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1 ⬇️

MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial

Microdroplet digital PCR: detection and quantitation of biomarkers in archived tissue and serial plasma samples in patients with lung cancer

Nedaplatin: a new platinum for squamous lung cancer?

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with

Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication

Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience

Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).

Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer

Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer ⬇️

Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009.

Targeting folate receptor alpha for cancer treatment

The impact of socioeconomic status on access to cancer clinical trials

The role of the HGF/Met axis in mesothelioma.

Therapeutic targets and new directions for antibodies developed for ovarian cancer.

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial